TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo

References

• Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267:1445-9; PMID:7878463; http://dx.doi.org/10.1126/science.7878-463
   PubMed Web of Science ®Google Scholar
• Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12:1551-70; PMID:9620844; http://dx.doi.org/10.1101/gad.12.11.1551
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10.1016/1074-7613(95)90057-8
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90; PMID:8663110; http://dx.doi.org/10.1074/jbc.271.22.12687
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14:5579-88; PMID:8521815
   PubMed Web of Science ®Google Scholar
• Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-67; PMID:10358762; http://dx.doi.org/10.1146/annurev.immunol.17.1.331
   PubMed Web of Science ®Google Scholar
• Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, Straus SE, Lenardo MJ. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004; 167:735-44; PMID:15557123; http://dx.doi.org/10.1083/jcb.200406101
   PubMed Web of Science ®Google Scholar
• Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10:348-55; PMID:19295631; http://dx.doi.org/10.1038/ni.1714
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20; PMID:9430226; http://dx.doi.org/10.1016/S1074-7613(00)80399-4
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70; PMID:9314565; http://dx.doi.org/10.1084/jem.186.7.1165
   PubMed Web of Science ®Google Scholar
• Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7:1003-6; PMID:9382840; http://dx.doi.org/10.1016/S0960-9822(06)00422-2
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19; PMID:9108485; http://dx.doi.org/10.1016/S0092-8674(00)80209-3
   PubMed Web of Science ®Google Scholar
• Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-97; PMID:9311998; http://dx.doi.org/10.1093/emboj/16.17.5386
   PubMed Web of Science ®Google Scholar
• Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3; PMID:9082980; http://dx.doi.org/10.1126/science.276.5309.111
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63; PMID:9930862; http://dx.doi.org/10.1038/5517
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30; PMID:12189384; http://dx.doi.org/10.1038/nrc821
   PubMed Web of Science ®Google Scholar
• Koschny R, Walczak H, Ganten TM. The promise of TRAIL–potential and risks of a novel anticancer therapy. J Mol Med (Berl) 2007; 85:923-35; PMID:17437073; http://dx.doi.org/10.1007/s00109-007-0194-1
   PubMed Web of Science ®Google Scholar
• Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8; PMID:11561060
   PubMed Web of Science ®Google Scholar
• Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351-4; PMID:10875917; http://dx.doi.org/10.1126/science.288.5475.2351
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39:633-40; PMID:10651627; http://dx.doi.org/10.1021/bi992242l
   PubMed Web of Science ®Google Scholar
• Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280:2205-12; PMID:15520016; http://dx.doi.org/10.1074/jbc.M410660200
   PubMed Web of Science ®Google Scholar
• Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-41; PMID:15846298; http://dx.doi.org/10.1038/sj.bjc.6602487
   PubMed Web of Science ®Google Scholar
• Li J, Knee DA, Wang YZ, Zhang QX, Johnson JA, Cheng J, He H, Miller C, Li ZF, Kowal C et al. LBY135, a novel anti-DR5 agonistic antibody induces tumor cell-specific cytotoxic activity in human colon tumor cell lines and xenografts. Drug Dev Res 2008; 69:69-82; http://dx.doi.org/10.1002/ddr.20229
   Web of Science ®Google Scholar
• Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, Fujiwara K. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008; 19:1060-7; PMID:18304965; http://dx.doi.org/10.1093/annonc/mdn015
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhang Z, Shi J, Liu S, Liu Y, Zheng D. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth. IUBMB Life 2012; 64:757-65; PMID:22815059; http://dx.doi.org/10.1002/iub.1064
   PubMed Web of Science ®Google Scholar
• Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, Pujol JL, Kozielski J, Baker N, Smethurst D et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:4442-51; PMID:22010015; http://dx.doi.org/10.1200/JCO.2011.37.2623
   PubMed Web of Science ®Google Scholar
• Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102:506-12; PMID:20068564; http://dx.doi.org/10.1038/sj.bjc.6605507
   PubMed Web of Science ®Google Scholar
• Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, Fischer C, Branschadel M, Abhari BA, Hohenberger P et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013; 12:2735-47; PMID:24101228; http://dx.doi.org/10.1158/1535-7163.MCT-13-0323
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3-10; PMID:15848070; http://dx.doi.org/10.1016/j.ymeth.2005.01.001
   PubMed Web of Science ®Google Scholar
• Mom CH, Verweij J, Oldenhuis CNAM, Gietema JA, Fox NL, Miceli R, Eskens FALM, Loos WJ, de Vries EGE, Sleijfer S. Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. Clin Cancer Res 2009; 15:5584-90; PMID:19690193; http://dx.doi.org/10.1158/1078-0432.CCR-09-0996
   PubMed Web of Science ®Google Scholar
• Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61:82-90; PMID:18255187; http://dx.doi.org/10.1016/j.lungcan.2007.12.011
   PubMed Web of Science ®Google Scholar
• von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL, Camidge DR. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2014; 15:188-96 e2; PMID:24560012; http://dx.doi.org/10.1016/j.cllc.2013.12.005
   PubMed Web of Science ®Google Scholar
• Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, Kadowaki S, Takahashi K, Sugiyama T, Kishi H et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med 2009; 15:1088-92; PMID:19684583; http://dx.doi.org/10.1038/nm.1966
   PubMed Web of Science ®Google Scholar
• Ishida I, Tomizuka K, Yoshida H, Tahara T, Takahashi N, Ohguma A, Tanaka S, Umehashi M, Maeda H, Nozaki C et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4:91-102; PMID:12006160; http://dx.doi.org/10.1089/153623002753632084
   PubMedGoogle Scholar
• Jin A, Ozawa T, Tajiri K, Lin Z, Obata T, Ishida I, Kishi H, Muraguchi A. Generation of TRAIL-receptor 1-specific human monoclonal Ab by a combination of immunospot array assay on a chip and human Ab-producing mice. Eur J Immunol 2010; 40:3591-3; PMID:21072874; http://dx.doi.org/10.1002/eji.201040551
   PubMed Web of Science ®Google Scholar
• Baumgarth N. Secreted IgM versus BLyS in germinal center formation. Nat Immunol 2000; 1:179; PMID:10973267; http://dx.doi.org/10.1038/79708
   PubMed Web of Science ®Google Scholar
• Vollmers HP, Brandlein S. Natural antibodies and cancer. N Biotechnol 2009; 25:294-8; PMID:19442595; http://dx.doi.org/10.1016/j.nbt.2009.03.016
   PubMed Web of Science ®Google Scholar
• Eskeland T, Christensen TB. IgM molecules with and without J chain in serum and after purification, studied by ultracentrifugation, electrophoresis, and electron microscopy. Scandinavian J Immunol 1975; 4:217-28; PMID:807966; http://dx.doi.org/10.1111/j.1365-3083.1975.tb02620.x
   PubMed Web of Science ®Google Scholar
• Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004; 20:755-62; PMID:15307922; http://dx.doi.org/10.1089/088-9222041524571
   PubMed Web of Science ®Google Scholar
• Wolbank S, Kunert R, Stiegler G, Katinger H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 2003; 77:4095-103; PMID:12634368; http://dx.doi.org/10.1128/JVI.77.7.4095-4103.2003
   PubMed Web of Science ®Google Scholar
• Wiersma EJ, Collins C, Fazel S, Shulman MJ. Structural and functional analysis of J chain-deficient IgM. J Immunol 1998; 160:5979-89 ; PMID:9637512
   PubMed Web of Science ®Google Scholar
• Strater J, Walczak H, Pukrop T, Von Muller L, Hasel C, Kornmann M, Mertens T, Moller P. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 2002; 122:659-66; PMID:11874999; http://dx.doi.org/10.1053/gast.2002.31889
   PubMed Web of Science ®Google Scholar
• Chaudhary KS, Abel PD, Stamp GW, Lalani E. Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol 2001; 193:522-9; PMID:11276013; http://dx.doi.org/10.1002/1096-9896(2000)9999:9999%3c::AID-PATH821%3e3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004; 7:139-56; PMID:15158769; http://dx.doi.org/10.1016/j.drup.2004.03.002
   PubMed Web of Science ®Google Scholar
• Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC cancer 2005; 5:54; PMID:15916713; http://dx.doi.org/10.1186/1471-2407-5-54
   PubMed Web of Science ®Google Scholar
• Herbeuval JP, Lambert C, Sabido O, Cottier M, Fournel P, Dy M, Genin C. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J Natl Cancer Inst 2003; 95:611-21; PMID:12697854; http://dx.doi.org/10.1093/jnci/95.8.611
   PubMedGoogle Scholar
• Petrusic V, Zivkovic I, Stojanovic M, Stojicevic I, Marinkovic E, Inic-Kanada A, Dimitijevic L. Antigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymers. Immunol Res 2011; 51:97-107; PMID:21786026; http://dx.doi.org/10.1007/s12026-011-8236-8
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013; 341:1192-8; PMID:24031011; http://dx.doi.org/10.1126/science.1241145
   PubMed Web of Science ®Google Scholar
• Tchoudakova A, Hensel F, Murillo A, Eng B, Foley M, Smith L, Schoenen F, Hildebrand A, Kelter AR, Ilag LL et al. High level expression of functional human IgMs in human PER.C6 cells. MAbs 2009; 1:163-71; PMID:20061826; http://dx.doi.org/10.4161/mabs.1.2.7945
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharmaceutical Sci 2004; 93:2645-68; PMID:15389672; http://dx.doi.org/10.1002/jps.20178
   PubMed Web of Science ®Google Scholar
• Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15:751-61; PMID:18219321; http://dx.doi.org/10.1038/sj.cdd.4402306
   PubMed Web of Science ®Google Scholar
• Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Therapy 2010; 9:618-31; PMID:20150762; http://dx.doi.org/10.4161/cbt.9.8.11264
   PubMed Web of Science ®Google Scholar
• Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005; 62:165-86; PMID:15389801; http://dx.doi.org/10.1002/pros.20126
   PubMed Web of Science ®Google Scholar
• Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ, Findlay DM. Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL. J Orthop Surg 2001; 9:19-22; PMID:12118126
   PubMedGoogle Scholar
• LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274-81; PMID:11875499; http://dx.doi.org/10.1038/nm0302-274
   PubMed Web of Science ®Google Scholar
• Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karstedt S, Graves J, Walczak H. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 2015; 34:2138-44; PMID:24909167; http://dx.doi.org/10.1038/onc.2014.156
   PubMed Web of Science ®Google Scholar
• Lin ZH, Jin A, Ozawa T, Tajiri K, Obata T, Ishida I, Jin F, Kishi H, Muraguchi A. Post-translational modification of TRAIL receptor type 1 on various tumor cells and the susceptibility of tumors to TRAIL-induced apoptosis. Biochem Biophys Res Commun 2010; 395:251-7; PMID:20363213; http://dx.doi.org/10.1016/j.bbrc.2010.03.175
   PubMed Web of Science ®Google Scholar
• Sorensen V, Rasmussen IB, Norderhaug L, Natvig I, Michaelsen TE, Sandlie I. Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG. J Immunol 1996; 156:2858-65; PMID:8609405
   PubMed Web of Science ®Google Scholar